SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported fourth quarter and full year 2021 financial results and provided business highlights.
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.